Top 50 Ai For Computational Biology in LATAM

The startup specializes in identifying bioactive ribonucleic acid (RNA) from natural sources using machine learning and bioinformatics techniques. This enables researchers to enhance human health and resilience in response to environmental stressors through the application of RNA technologies.

Eugit develops novel tissue targeting therapies for complex diseases. The company leverages expertise in computational genomics and immunology to design precise therapeutic approaches. Their focus is on creating treatments that selectively engage specific biological targets within diseased tissues.

Onc.ai develops AI models leveraging oncology real-world data, including imaging, EMR, and genomics, to enhance precision oncology. The company's deep learning imaging AI aims to bring clarity to cancer treatment decision-making for medical oncologists. Initial products focus on predicting clinical outcomes in metastatic lung cancer to support pharmaceutical clinical development.

Embryoxite develops an AI-powered platform that analyzes embryo metabolomic data, genetic profiles, and morphokinetic imaging to assess implantation potential in pre-implantation embryos. This technology addresses the high failure rate of embryo implantation in IVF procedures by providing objective, data-driven insights that enhance selection accuracy and improve pregnancy outcomes.

Nintx develops next-generation pharmaceutical and nutraceutical therapies by translating complex intra- and interspecies biological interactions into novel treatments. The company leverages proprietary omics and data analytics technologies to discover natural product ingredients that modulate human biological targets and the gut microbiome. This platform focuses on creating multi-target solutions for multifactorial diseases linked to human biology and microbial crosstalk.

Biotango utilizes genomic editing and climate data analysis to enhance the productivity and quality of fruit crops, addressing the significant food waste and economic losses in agriculture. By predicting crop behavior under varying climatic conditions, the company aims to improve yield efficiency and reduce losses in fruit production by up to 30%.

Genica creates science‑based bioinsumos—including microbial inoculants, bio‑fungicides, bio‑nematicides, and organomineral fertilizers—to improve nutrient use efficiency, plant resilience, and disease control for Brazilian row‑crop growers. By applying advanced microbiology, molecular screening, and bioinformatics, its products deliver higher yields while reducing reliance on synthetic chemicals, supporting sustainable and climate‑resilient agriculture.

Clear Labs is a biotechnology firm that utilizes a genomics system to enhance diagnostic accuracy in clinical and application sectors. The company addresses the complexity of traditional diagnostic processes by providing streamlined genomic analysis, enabling faster and more reliable results.

This company develops co-processors utilizing biological neurons as an alternative to traditional silicon-based computing. Their neuron systems offer adaptable architecture, stable power consumption, and high fault tolerance compared to fixed transistor systems. These bio-processors are applied across security, military, and agriculture sectors for advanced sensory detection and analysis.

Rosebud Biosciences develops targeted therapies for rare pediatric genetic diseases using patient-specific organoid models. The company engineers micropatterned 2.5D organoids from induced pluripotent stem cells that replicate individual genetic mutations for drug screening. This platform enables the high-throughput testing of small molecules, gene therapies, and RNA therapeutics against complex developmental disorders.

BioHeuris combines synthetic biology and gene editing to create herbicide-resistant crops that enable sustainable weed management. This approach reduces the reliance on toxic herbicides and mitigates the evolution of herbicide-resistant weeds, promoting environmental sustainability in agriculture.

Terraflos is a Consumer Science Company that discovers and scales bioactive compounds from Latin American plants into evidence‑based, plant‑based supplements, hyperfoods, and dermocosmetics. Using AI‑guided screening and scientific validation, it creates sustainable, nutritionally dense products and offers B2B R&D and CDMO services to help other wellness brands launch functional, data‑backed offerings.

Huna develops an AI engine that analyzes routine blood test data to identify risk patterns for early cancer detection and other chronic diseases. This technology enables healthcare providers to classify patients by risk level, improving clinical decision-making and increasing the chances of successful treatment while reducing overall healthcare costs.

The startup has developed a molecular testing platform that utilizes low-cost tools for on-site analysis of DNA, RNA, and protein targets. This technology enables businesses to make real-time decisions regarding food quality and health by providing precise and accessible testing services.

Comsentimento develops an AI-driven platform for clinical data transformation and research, focusing on enhancing cancer treatment and facilitating access to clinical trials. The platform provides healthcare professionals with actionable insights and support for chronic disease management, improving patient care and treatment adherence.

Arkangel AI is a no-code platform that transforms medical data into AI algorithms for early disease detection, enabling healthcare organizations to build and deploy tailored solutions efficiently. By streamlining processes such as patient triage and drug adverse effect prediction, Arkangel AI enhances healthcare outcomes while significantly reducing operational costs.

The startup utilizes a bio-based technological platform that employs genetic engineering tools and microalgae to produce valuable proteins and compounds, such as hirudin, which is traditionally sourced from sponges. This approach provides a sustainable and cost-effective solution for companies seeking hard-to-find biochemical compounds.

The startup develops an all-in-one AI platform that integrates knowledge engineering into large enterprises through data engineering, customized models, and content creation tools. This technology enables businesses to optimize operations and drive growth by effectively managing and utilizing their data resources.

The startup has developed a clinical research platform that utilizes machine learning to target the biological processes of aging, facilitating the discovery of therapies for age-related diseases such as cardiovascular and neurodegenerative conditions. By enabling pharmaceutical companies to enhance medical treatments, the platform addresses the need for more effective interventions in aging-related health issues.

CellRep develops an AI-powered platform to discover and validate compounds for non-genetic cell reprogramming. This approach optimizes cellular function to enhance therapeutic potential, addressing limitations in current cell therapies like CAR-T treatments. The company provides an end-to-end pipeline from target discovery through preclinical validation for applications in oncology and longevity.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

metaBIX develops advanced computational tools for accelerating drug discovery pipelines. The platform integrates machine learning models with high-throughput screening data to predict compound efficacy and toxicity profiles. This capability allows pharmaceutical researchers to rapidly identify viable therapeutic candidates with optimized physicochemical properties.

Base Cientifica offers comprehensive molecular and cellular research services to accelerate preclinical development and personalized medicine. They specialize in biological assay validation, biobanking, and molecular diagnostic assay development using PCR and NGS. Their services also include preclinical efficacy and safety studies, 3D organoid cultivation, and AI-driven R&D optimization.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

Beeing Company utilizes artificial intelligence and neural networks to perform genetic analysis of honey bee queens, ensuring the preservation of bee species and promoting biodiversity. Their certification process guarantees that beekeepers can verify the quality and health of their bees, facilitating access to international markets.

The startup develops AI-powered applications that enhance decision-making by analyzing large datasets and providing actionable insights. This technology enables organizations to make data-driven choices more efficiently, reducing uncertainty and improving operational outcomes.

The startup has developed a molecular diagnostic platform that integrates advanced fluidics, engineering, and bioinformatics to create a user-friendly in vitro diagnostic system. This technology enables healthcare providers to deliver precise clinical genomic information to patients, enhancing accessibility to essential diagnostics for improved treatment outcomes.

The startup offers an AI-driven platform that connects businesses with suitable partners throughout their innovation journey. By leveraging machine learning algorithms, it enhances strategic collaboration, enabling companies to identify and engage with startups that align with their specific needs.

Diag-Nose.io develops the RhinoMAP platform to decode airway biology for respiratory diseases. This platform integrates nasal microsampling, proteomics, and machine learning algorithms to analyze biomarker data. The goal is to enable precision medicine by identifying root causes, leading to faster, more effective treatment selection for patients.

This startup provides personalized medicines through genetic testing and data analysis, enabling microgram-level customization of treatments. By tracking the entire treatment journey, it offers patients affordable, tailored medications and real-time updates on their health status.

TAXON utilizes artificial intelligence and genomic analysis to enhance soil microbiome understanding, enabling farmers and biotech companies to optimize crop yields and reduce reliance on agrochemicals. By providing detailed insights into microbial diversity and functionality, TAXON helps clients make informed decisions that lead to sustainable agricultural practices and improved productivity.

Kinzbio develops phage-based precision antimicrobials to combat antibiotic-resistant infections quickly and effectively. Their platform utilizes AI-driven software and proprietary databases to deliver personalized, pharmaceutical-grade therapies within 5 to 15 days. The company also engineers solutions for infection prevention in clinical settings, targeting harmful bacteria with high specificity.

Entelai provides AI-driven diagnostic tools for the healthcare sector in Latin America, enhancing the accuracy of medical image analysis and optimizing physician workflows. Their solutions address the challenges of diagnostic precision and resource utilization, ultimately improving patient care and satisfaction.

The startup develops predictions-based artificial intelligence software that analyzes data to create accurate predictive models, minimizing human error. This technology enhances operational efficiency and competitiveness for clients across various business processes by transforming raw data into actionable insights.

Aperture Therapeutics develops oligonucleotide therapeutics by identifying naturally occurring gene variants that confer protection against neurodegenerative diseases. The platform uses machine learning to analyze genomic and clinical datasets to prioritize protective gene variants for therapeutic mimicry. This approach targets genetically validated pathways to address shared drivers in ALS and FTD, expanding patient applicability beyond rare mutations.

The startup offers an ecosystem of AI agent-based tools that enhance human capabilities by facilitating the design, execution, and monitoring of collaborative processes between humans and AI. This approach addresses the challenges of inefficient workflows and communication, enabling users to improve productivity and decision-making through increased cognitive support and skill development.

This startup has developed a biotech platform that enhances the drug discovery process through predictive toxicology and drug quality assurance, specifically tailored for the Latin American market. By optimizing research and development workflows, the platform reduces time and costs while minimizing the reliance on animal testing.

Yeda Health utilizes artificial intelligence to provide personalized dietary and lifestyle recommendations based on individual responses to food and continuous glucose monitoring data. This approach addresses the challenge of managing blood glucose levels by recognizing that each person's metabolic response is unique, enabling tailored strategies for metabolic stability.

Inkus provides genetic and genomic solutions to enhance the productivity and resilience of aquaculture species through precision breeding techniques. The startup addresses the challenges of low yield and vulnerability to disease in the aquaculture industry, enabling sustainable growth and improved stock performance.

Multiplex.bio offers advanced molecular diagnostics for plant viruses and viroids using high-throughput sequencing and its proprietary Viroscope™ algorithm. This platform provides high diagnostic certainty by correlating viral genome coverage with biological infectivity, ensuring accurate detection for plant health management.

OmniTier Storage provides on-premise genomic analysis appliances that utilize AI-based variant interpretation to enhance the accuracy and speed of diagnosing rare genetic diseases. By automating secondary analysis and supporting multiple sequencing technologies, the platform enables researchers and clinicians to efficiently implement custom methodologies while maintaining control over patient data and reducing costs.

MYNU is a biotechnology startup that utilizes genetic testing to analyze over 130 genes, creating personalized nutrition plans tailored to individual genetic profiles. By combining biotechnological research and artificial intelligence, MYNU addresses the need for customized dietary solutions that enhance personal well-being and support specific health goals.

The startup utilizes a proprietary Generative Biology Platform and a Discovery Platform that integrate machine learning and multi-modal single-cell analysis to identify gene regulatory networks and develop targeted cell therapies for cancer. By precisely modulating gene expression in specific cell types, the company aims to enhance the efficacy of cell-based treatments, addressing the limitations of traditional cancer therapies.

Naturannova utilizes a computational platform that combines AI and bioinformatics to identify and analyze plant-based proteins, creating sustainable and clean label ingredients. The startup addresses the need for healthier food options by developing novel protein sources, such as their all-natural protein-based sweetener, through precision fermentation and laboratory testing.

The startup develops a DNA-based affinity test kit that analyzes genetic variants affecting drug metabolism, enabling personalized treatment plans for patients. This approach minimizes adverse drug reactions and enhances therapeutic efficacy by tailoring medications to individual genetic profiles.

Gbot develops a high-throughput phenotyping platform that utilizes autonomous ground vehicles and AI to automate data collection and analysis for crop characterization. This technology addresses the limitations in plant breeding by providing accurate, large-scale crop information essential for enhancing global food production.

The startup provides customizable, scalable AI models via API integration for open-pit industries, enhancing operational efficiency and decision-making processes. Their technology addresses the need for tailored data solutions that seamlessly fit into existing business workflows.

This startup is developing Artificial General Intelligence (AGI) using advanced neural network architectures and reinforcement learning techniques to create systems that can perform any intellectual task a human can. The technology aims to enhance decision-making processes across various industries by providing machines with the ability to understand, learn, and adapt to complex environments.

BlackGenn integrates synthetic biology, genomics, metagenomics, and metabolomics to expedite the development of new bioproducts. The startup addresses the slow and costly process of bioproduct generation by streamlining the research and development pipeline.

Phenoscience provides a cloud‑native platform for managing, analyzing, and visualizing large phenotypic datasets. It offers automated pipelines for data cleaning, statistical testing, clustering, and machine‑learning‑driven trait extraction, with version‑controlled storage, role‑based access, and API/SDK integration for seamless workflow collaboration.